Notably, in addition to T‐ALL, LMO2 is expressed in hematologic cancer of the B‐cell lineage including DLBCL (Natkunam et al, 2007; Cubedo et al, 2012) and BCP‐ALL (de Boer et al, 2011; Malumbres et al, 2011; Deucher et al, 2015). Here, LMO2 is linked to hematopoietic and lymphoid cell neoplasm.